Deciphera Pharmaceuticals Inc (DCPH) Receives Consensus Rating of “Buy” from Brokerages

Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $43.40.

Several research firms recently commented on DCPH. BidaskClub raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Zacks Investment Research raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a report on Tuesday, January 9th. Nomura began coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target for the company. Piper Jaffray Companies began coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target for the company. Finally, Instinet began coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target for the company.

Deciphera Pharmaceuticals (DCPH) traded up $1.43 during trading hours on Friday, hitting $27.47. The company had a trading volume of 173,942 shares, compared to its average volume of 184,508. Deciphera Pharmaceuticals has a 12-month low of $15.15 and a 12-month high of $27.53.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($5.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($5.30). research analysts forecast that Deciphera Pharmaceuticals will post -2.91 EPS for the current year.

A number of institutional investors have recently modified their holdings of DCPH. Orbimed Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $7,487,000. Emerald Advisers Inc. PA purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $6,661,000. Emerald Mutual Fund Advisers Trust purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $5,548,000. Citadel Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $4,965,000. Finally, Kornitzer Capital Management Inc. KS purchased a new position in Deciphera Pharmaceuticals in the third quarter worth approximately $2,172,000. Institutional investors own 43.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/19/deciphera-pharmaceuticals-inc-dcph-receives-consensus-rating-of-buy-from-brokerages.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply